Free Trial

Olema Pharmaceuticals (OLMA) Stock Price, News & Analysis

Olema Pharmaceuticals logo
$5.46 -0.06 (-1.09%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$5.44 -0.02 (-0.37%)
As of 08/29/2025 06:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Olema Pharmaceuticals Stock (NASDAQ:OLMA)

Key Stats

Today's Range
$5.39
$5.64
50-Day Range
$4.19
$5.76
52-Week Range
$2.86
$13.93
Volume
302,991 shs
Average Volume
470,885 shs
Market Capitalization
$374.72 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$24.00
Consensus Rating
Moderate Buy

Company Overview

Olema Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
38th Percentile Overall Score

OLMA MarketRank™: 

Olema Pharmaceuticals scored higher than 38% of companies evaluated by MarketBeat, and ranked 739th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Olema Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 5 buy ratings, no hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Olema Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

  • Read more about Olema Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Olema Pharmaceuticals are expected to decrease in the coming year, from ($2.33) to ($2.62) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Olema Pharmaceuticals is -2.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Olema Pharmaceuticals is -2.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Olema Pharmaceuticals has a P/B Ratio of 1.09. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Olema Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    13.35% of the float of Olema Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Olema Pharmaceuticals has a short interest ratio ("days to cover") of 11.3, which indicates bearish sentiment.
  • Change versus previous month

  • Dividend Yield

    Olema Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Olema Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    13.35% of the float of Olema Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Olema Pharmaceuticals has a short interest ratio ("days to cover") of 11.3, which indicates bearish sentiment.
  • Change versus previous month

  • News Sentiment

    Olema Pharmaceuticals has a news sentiment score of 1.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.09 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Olema Pharmaceuticals this week, compared to 3 articles on an average week.
  • Search Interest

    4 people have searched for OLMA on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added Olema Pharmaceuticals to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Olema Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    16.36% of the stock of Olema Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    91.78% of the stock of Olema Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Olema Pharmaceuticals' insider trading history.
Receive OLMA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Olema Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

OLMA Stock News Headlines

Man Who Called Nvidia at $1.10 Says Buy This Now...
In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new company could become the next to soar like Nvidia.tc pixel
See More Headlines

OLMA Stock Analysis - Frequently Asked Questions

Olema Pharmaceuticals' stock was trading at $5.83 on January 1st, 2025. Since then, OLMA shares have decreased by 6.3% and is now trading at $5.46.

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) issued its quarterly earnings results on Monday, August, 11th. The company reported ($0.51) EPS for the quarter, missing analysts' consensus estimates of ($0.43) by $0.08.

Olema Pharmaceuticals (OLMA) raised $170 million in an IPO on Thursday, November 19th 2020. The company issued 10,000,000 shares at $16.00-$18.00 per share. J.P. Morgan, Jefferies, Cowen and Canaccord Genuity served as the underwriters for the IPO.

Olema Pharmaceuticals' top institutional investors include MPM Bioimpact LLC (3.47%), Geode Capital Management LLC (1.94%), Ameriprise Financial Inc. (1.71%) and Bank of America Corp DE (1.16%). Insiders that own company stock include Bain Capital Life Sciences Inv, Bvf Partners L P/Il, Biocapital Advisors L Paradigm, Cyrus Harmon, David C Myles, Sean Bohen and Naseem Zojwalla.
View institutional ownership trends
.

Shares of OLMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Olema Pharmaceuticals investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), e.l.f. Beauty (ELF) and Jabil (JBL).

Company Calendar

Last Earnings
8/11/2025
Today
8/30/2025
Next Earnings (Estimated)
11/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:OLMA
CIK
1750284
Fax
N/A
Employees
70
Year Founded
N/A

Price Target and Rating

High Price Target
$30.00
Low Price Target
$18.00
Potential Upside/Downside
+339.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
6 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.98)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$129.47 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-42.58%
Return on Assets
-38.65%

Debt

Debt-to-Equity Ratio
0.01
Current Ratio
11.09
Quick Ratio
11.09

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$5.03 per share
Price / Book
1.09

Miscellaneous

Outstanding Shares
68,630,000
Free Float
57,405,000
Market Cap
$374.72 million
Optionable
Optionable
Beta
1.92

Social Links

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:OLMA) was last updated on 8/31/2025 by MarketBeat.com Staff
From Our Partners